Sernova Corp. (SVA.TO)
CAD 0.21
(7.69%)
CAD 0.21
(7.69%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 22.1 Million CAD | -57.88% |
| 2022 | 52.48 Million CAD | 76.0% |
| 2021 | 29.82 Million CAD | 420.83% |
| 2020 | 5.72 Million CAD | 2.82% |
| 2019 | 5.56 Million CAD | 54.46% |
| 2018 | 3.6 Million CAD | -20.79% |
| 2017 | 4.55 Million CAD | -26.89% |
| 2016 | 6.22 Million CAD | 97.42% |
| 2015 | 3.15 Million CAD | -21.58% |
| 2014 | 4.02 Million CAD | -35.6% |
| 2013 | 6.24 Million CAD | 0.66% |
| 2012 | 6.2 Million CAD | 55.95% |
| 2011 | 3.97 Million CAD | -1.42% |
| 2010 | 4.03 Million CAD | -10.19% |
| 2009 | 4.49 Million CAD | -12.77% |
| 2008 | 5.14 Million CAD | -28.8% |
| 2007 | 7.23 Million CAD | 8.0% |
| 2006 | 6.69 Million CAD | 1262.07% |
| 2005 | 491.66 Thousand CAD | 45.9% |
| 2004 | 336.98 Thousand CAD | -16.01% |
| 2003 | 401.24 Thousand CAD | -30.21% |
| 2002 | 574.92 Thousand CAD | -67.77% |
| 2001 | 1.78 Million CAD | -25.8% |
| 2000 | 2.4 Million CAD | 443.05% |
| 1999 | 442.68 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 18.57 Million CAD | -15.99% |
| 2024 Q2 | 11.76 Million CAD | -36.65% |
| 2024 Q3 | 7.45 Million CAD | -36.63% |
| 2023 FY | 22.1 Million CAD | -57.88% |
| 2023 Q4 | 22.1 Million CAD | -33.42% |
| 2023 Q1 | 46.96 Million CAD | -10.53% |
| 2023 Q3 | 33.2 Million CAD | -12.71% |
| 2023 Q2 | 38.03 Million CAD | -19.0% |
| 2022 FY | 52.48 Million CAD | 76.0% |
| 2022 Q2 | 26.71 Million CAD | -9.45% |
| 2022 Q3 | 44.58 Million CAD | 66.87% |
| 2022 Q1 | 29.5 Million CAD | -1.05% |
| 2022 Q4 | 52.48 Million CAD | 17.72% |
| 2021 Q1 | 10.67 Million CAD | 86.37% |
| 2021 Q3 | 31.32 Million CAD | -3.65% |
| 2021 FY | 29.82 Million CAD | 420.83% |
| 2021 Q4 | 29.82 Million CAD | -4.79% |
| 2021 Q2 | 32.5 Million CAD | 204.64% |
| 2020 Q1 | 4.21 Million CAD | -24.28% |
| 2020 Q3 | 2.9 Million CAD | -8.65% |
| 2020 Q4 | 5.72 Million CAD | 96.88% |
| 2020 FY | 5.72 Million CAD | 2.82% |
| 2020 Q2 | 3.18 Million CAD | -24.5% |
| 2019 Q1 | 3.09 Million CAD | -14.02% |
| 2019 Q4 | 5.56 Million CAD | 173.96% |
| 2019 Q3 | 2.03 Million CAD | -26.53% |
| 2019 FY | 5.56 Million CAD | 54.46% |
| 2019 Q2 | 2.76 Million CAD | -10.74% |
| 2018 Q3 | 4.51 Million CAD | 55.89% |
| 2018 Q4 | 3.6 Million CAD | -20.21% |
| 2018 Q1 | 3.76 Million CAD | -17.29% |
| 2018 Q2 | 2.89 Million CAD | -23.01% |
| 2018 FY | 3.6 Million CAD | -20.79% |
| 2017 Q4 | 4.55 Million CAD | -18.39% |
| 2017 FY | 4.55 Million CAD | -26.89% |
| 2017 Q3 | 5.57 Million CAD | -4.22% |
| 2017 Q2 | 5.82 Million CAD | -1.95% |
| 2017 Q1 | 5.93 Million CAD | -4.6% |
| 2016 FY | 6.22 Million CAD | 97.42% |
| 2016 Q4 | 6.22 Million CAD | -3.76% |
| 2016 Q3 | 6.46 Million CAD | 109.55% |
| 2016 Q2 | 3.08 Million CAD | -17.72% |
| 2016 Q1 | 3.75 Million CAD | 18.98% |
| 2015 Q4 | 3.15 Million CAD | -17.33% |
| 2015 FY | 3.15 Million CAD | -21.58% |
| 2015 Q1 | 3.31 Million CAD | -17.44% |
| 2015 Q3 | 3.81 Million CAD | 38.31% |
| 2015 Q2 | 2.75 Million CAD | -16.93% |
| 2014 Q2 | 5.13 Million CAD | -8.94% |
| 2014 FY | 4.02 Million CAD | -35.6% |
| 2014 Q3 | 4.66 Million CAD | -9.09% |
| 2014 Q4 | 4.02 Million CAD | -13.82% |
| 2014 Q1 | 5.63 Million CAD | -9.73% |
| 2013 Q1 | 7.71 Million CAD | 24.45% |
| 2013 FY | 6.24 Million CAD | 0.66% |
| 2013 Q4 | 6.24 Million CAD | -6.39% |
| 2013 Q3 | 6.66 Million CAD | -5.98% |
| 2013 Q2 | 7.09 Million CAD | -8.1% |
| 2012 Q3 | 6.78 Million CAD | -4.39% |
| 2012 Q1 | 3.38 Million CAD | -14.93% |
| 2012 FY | 6.2 Million CAD | 55.95% |
| 2012 Q2 | 7.1 Million CAD | 109.88% |
| 2012 Q4 | 6.2 Million CAD | -8.64% |
| 2011 Q3 | 4.14 Million CAD | 12.77% |
| 2011 FY | 3.97 Million CAD | -1.42% |
| 2011 Q1 | 4.2 Million CAD | 4.19% |
| 2011 Q2 | 3.67 Million CAD | -12.63% |
| 2011 Q4 | 3.97 Million CAD | -3.96% |
| 2010 Q1 | 4.14 Million CAD | -7.83% |
| 2010 FY | 4.03 Million CAD | -10.19% |
| 2010 Q4 | 4.03 Million CAD | 3.07% |
| 2010 Q3 | 3.91 Million CAD | -5.82% |
| 2010 Q2 | 4.15 Million CAD | 0.39% |
| 2009 FY | 4.49 Million CAD | -12.77% |
| 2009 Q2 | 4.47 Million CAD | -7.22% |
| 2009 Q3 | 4.5 Million CAD | 0.56% |
| 2009 Q4 | 4.49 Million CAD | -0.28% |
| 2009 Q1 | 4.82 Million CAD | -6.24% |
| 2008 Q1 | 6.65 Million CAD | -8.05% |
| 2008 Q3 | 5.54 Million CAD | -8.96% |
| 2008 Q2 | 6.09 Million CAD | -8.39% |
| 2008 FY | 5.14 Million CAD | -28.8% |
| 2008 Q4 | 5.14 Million CAD | -7.16% |
| 2007 Q4 | 7.23 Million CAD | -4.15% |
| 2007 Q3 | 7.54 Million CAD | 14.78% |
| 2007 Q2 | 6.57 Million CAD | 5.54% |
| 2007 Q1 | 6.22 Million CAD | -6.99% |
| 2007 FY | 7.23 Million CAD | 8.0% |
| 2006 FY | 6.69 Million CAD | 1262.07% |
| 2006 Q4 | 6.69 Million CAD | 91.79% |
| 2006 Q3 | 3.49 Million CAD | 464.68% |
| 2006 Q2 | 618.36 Thousand CAD | 39.15% |
| 2006 Q1 | 444.39 Thousand CAD | -9.61% |
| 2005 Q2 | 145.65 Thousand CAD | -40.5% |
| 2005 Q4 | 491.66 Thousand CAD | -8.53% |
| 2005 FY | 491.66 Thousand CAD | 45.9% |
| 2005 Q3 | 537.52 Thousand CAD | 269.03% |
| 2005 Q1 | 244.81 Thousand CAD | -27.35% |
| 2004 Q4 | 336.98 Thousand CAD | -3.71% |
| 2004 Q1 | 368.15 Thousand CAD | -8.25% |
| 2004 FY | 336.98 Thousand CAD | -16.01% |
| 2004 Q2 | 434.43 Thousand CAD | 18.0% |
| 2004 Q3 | 349.97 Thousand CAD | -19.44% |
| 2003 Q3 | 519.67 Thousand CAD | -3.29% |
| 2003 Q4 | 401.24 Thousand CAD | -22.79% |
| 2003 Q2 | 537.36 Thousand CAD | -31.81% |
| 2003 Q1 | 788.05 Thousand CAD | 37.07% |
| 2003 FY | 401.24 Thousand CAD | -30.21% |
| 2002 Q1 | 1.28 Million CAD | 0.0% |
| 2002 FY | 574.92 Thousand CAD | -67.77% |
| 2002 Q2 | 739.49 Thousand CAD | -42.53% |
| 2002 Q3 | 440.4 Thousand CAD | -40.44% |
| 2002 Q4 | 574.92 Thousand CAD | 30.54% |
| 2001 FY | 1.78 Million CAD | -25.8% |
| 2000 FY | 2.4 Million CAD | 443.05% |
| 1999 FY | 442.68 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Appili Therapeutics Inc. | 1.49 Million CAD | -1383.278% |
| Eupraxia Pharmaceuticals Inc. | 26.72 Million CAD | 17.274% |
| Helix BioPharma Corp. | 1.48 Million CAD | -1384.675% |
| Microbix Biosystems Inc. | 35.65 Million CAD | 37.995% |
| Medicenna Therapeutics Corp. | 19.13 Million CAD | -15.537% |
| Satellos Bioscience Inc. | 44.29 Million CAD | 50.095% |
| Oncolytics Biotech Inc. | 38.82 Million CAD | 43.053% |